… the gastrointestinal toxic effects of anti-PD-1 treatment in … small-cell lung carcinoma, kidney
carcinoma, gastric cancer, etc… how to uncouple anti-tumor immunity from hazardous irAEs. …

… human embryonic kidney–293 cells transfected with mutated PD-1 constructs … while limiting
immune toxicities in other tissues. … identify target proteins to uncouple the impact of PD-1 on …

… of these agents to kidney toxicity has been neglected and … the anti-PD-1 antibody nivolumab
who developed kidney injury, … adding anti-tumor efficacy to PD-1 blockade in patients with …

… efficacy of molecular targeted therapies following nivolumab in metastatic … events on
PD-1 blockade therapy and was subsequently controlled using immune checkpoint inhibitor–mTOR …

… , the kidney is no exception to the rule and can be the target of … Switching from calcineurin
to mTOR inhibitors is an … of uncoupling anti-PD-1 therapy toxicity and efficacy, as mTOR …

… such as drug resistance, toxicity and patient heterogeneity, … to improving antitumor immune
efficacy and relieve exhaustion… PD-1, and ultimately improving the immune efficacy targeting …

… toxicity compared to ipilimumab[241]. There are numerous other reports and reviews on the
efficacy of PD-1 … response rates for anti-PD-1 therapy were 27% for renal-cell cancer, 28% …

… inhibitor to mammalian target of rapamycin (mTOR) inhibitor … to uncouple anticancer and
antiallograft immune response. … incidence of acute kidney injury compared with anti-PD-1. This …

… The intracellular domain of PD-1 becomes phosphorylated … ADCs generate toxicity on account
of the uncoupling of linkers … proliferation and metastasis of renal cancer cells by binding to …

… PD-1/PD-L1 blocking antibodies have garnered significant … Furthermore, clinical research
has substantiated the efficacy … mechanisms and identification of novel targets for PD-1/PD-L1 …